塞尔托雷克桑特用于严重抑郁症
Kyle Valentino1,2,3, Kayla M Teopiz1, Sabrina Wong1,2,3
1Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada.
Expert opinion on emerging drugs
|January 10, 2025
概括
塞尔托雷克桑是一种素受体对抗剂,对治疗严重抑郁症 (MDD) 有希望,特别是在严重睡眠障碍患者中. 需要进行进一步的III期试验,以确认其在抑郁症治疗中的有效性和安全性.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 素系统参与调节睡眠-清醒周期,奖励和认知,这表明精神障碍的治疗潜力.
- 现有的重大抑郁症 (MDD) 治疗方法在有效性和耐受性方面存在局限性,需要新的治疗方法.
- 塞尔托雷克桑 (Seltorexant) 是一种素受体对抗剂,是一种针对这些途径进行潜在的MDD治疗的研究化合物.
研究的目的:
- 审查素系统在MDD中的作用,重点关注睡眠和奖励机制.
- 评估seltorexant作为MDD的新疗法的安全性,耐受性和有效性.
- 讨论素受体对抗在抑郁症治疗中的更广泛影响.
主要方法:
- 在PubMed,Medline,Cochrane图书馆,Embase,Scopus和Web of Science的系统文献搜索从创立到2024年10月10日.
- 关于赛尔托雷克桑和奥雷克辛受体对抗性的临床前和临床数据的审查.
- 分析涉及MDD的机制,包括奖励和睡眠.
主要成果:
- 早期的临床证据表明,seltorexant在治疗MDD方面是有效的.
- 抗抑郁药的作用在患有严重睡眠障碍的MDD患者中更为明显.
- 塞尔托雷克桑特在有并发性失眠和没有并发性失眠的个体中都显示出有效性.
结论:
- 塞尔托雷克桑特通过向素系统,为MDD提供了一种潜在的新疗法.
- 该药物对患有严重睡眠障碍并患有抑郁症的患者特别有希望.
- 在大规模的III期临床试验中确认seltorexant的有效性和安全性至关重要.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
192
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
192
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
299
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
299
01:30Electroconvulsive Therapy
22
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
22
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
145
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
145
01:25Antidepressant Drugs: Overview
356
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
356
01:17Drugs for Treatment of Diarrhea-Predominant IBS
146
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
146